Treating the brain cancer glioblastoma (GBM) demands more than conventional strategies due to a mix of factors including the cancer’s genetic complexity, invasive growth, and immune resistance. A new ...
Immune Checkpoint Blockade (ICB) has revolutionized the treatment of cancers like melanoma, but up to 60% of patients don't ...
It is expected that the role of pDCs in MS will be more precisely defined in the near future. This will lead to clinical trials targeting specific molecules to modulate pDC functions. KE Balashov's ...
Researchers from Instituto de Investigación Sanitaria Hospital Universitario de La Princesa and collaborators have developed nanoparticles loaded with poly(I:C) and used them to prime monocyte-derived ...
Each year, approximately 36,000 people are diagnosed with the disease in the United States, according to the American Cancer ...
CD8 + cytotoxic T lymphocytes (CTLs) serve as central effectors in cancer immunotherapy by directly eliminating tumor cells. However, current clinical therapies face significant limitations. These ...
Researchers have shown that a particular type of immune cell acts more flexibly than previously thought -- with potential for new therapeutic approaches. LMU researchers have shown that a particular ...
Immunotherapy has been generally ineffective for prostate cancer because the tumors are considered immunologically "cold," meaning they do not attract enough immune cells to mount a strong attack.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results